Our research group, hosted within the Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO) at the University of Geneva, is dedicated to transforming cancer treatment through a systems-level understanding of drug action. We focus on developing optimized, personalized therapeutic strategies for complex diseases, primarily cancer.
Our core approach is highly interdisciplinary, integrating fundamental biological research with advanced pharmacological modeling. We employ a unique "bedside-to-bench-and-back" framework, meaning we start with clinical observations, investigate the underlying mechanisms in the lab, and then translate our findings back into clinically relevant, personalized treatment plans. This allows us to uncover novel signaling pathways, identify mechanisms of drug resistance, and discover new opportunities for drug development.
A key dimension of our work is the integration of genomic and multi-omics approaches to decode drug response variability . By leveraging pharmacogenomic data, we identify genomic markers that predict anti-cancer drug sensitivity, enabling the development of molecularly targeted therapies tailored to individual tumor genotypes. Our published research demonstrates the power of combining transcriptomic, lipidomic, and metabolomic profiling with systems pharmacology to unravel drug synergy mechanisms and resistance pathways in cancers such as colorectal and renal cell carcinoma. This genomics-informed strategy is central to our goal of designing synergistic combination therapies that are dynamically tailored to a patient's changing tumor response, thereby enhancing treatment efficacy, minimizing side effects, and reducing the likelihood of acquired resistance.